Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Liver Diseases

Free Subscription 20.10.2025 1 Am J Gastroenterol 1 Biochem Biophys Res Commun 2 BMC Cancer 1 BMC Gastroenterol 2 Dig Dis Sci 1 Eur J Pediatr 1 Gut 13 Hepatology 1 J Clin Oncol 1 J Gastroenterol 2 J Gastroenterol Hepatol 5 J Hepatol 1 Oncogene 7 PLoS One 3 Transplant Proc 1 Transplantation

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Gastroenterol

1. CHIRAPONGSATHORN S, Chang A, Malikhao S, Wanichagool D, et al
   One versus five days of octreotide infusion for acute esophageal variceal bleeding: a randomized controlled trial.
   Am J Gastroenterol. 2025 Oct 15. doi: 10.14309/ajg.0000000000003791.
   PubMed         Abstract available
   
   

   
   Biochem Biophys Res Commun

2. FU J, Chen T, Fang X, Zhang S, et al
   Immune cell subsets as therapeutic targets in liver fibrosis: from mechanisms to translational applications.
   Biochem Biophys Res Commun. 2025;785:152682.
   PubMed         Abstract available
   
   

   
   BMC Cancer

3. QIN Y, Zhou J, Li S, Liu X, et al
   SLIT2 modulates NMIIA to regulate mitophagy and suppress hepatocellular carcinoma progression.
   BMC Cancer. 2025;25:1561.
   PubMed         Abstract available
   
   
4. CHEN J, Hu Z, Li H, Su R, et al
   Machine learning predicts post-transplant muscle loss in hepatocellular carcinoma patients without sarcopenia.
   BMC Cancer. 2025;25:1565.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

5. BEHZAD C, Shateri Z, Motamed N, Maadi M, et al
   Association of cardiometabolic index with non-alcoholic fatty liver disease among Iranian adults of the amol cohort study.
   BMC Gastroenterol. 2025;25:729.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

6. TAN Y, Zhang X, Wang J, Xiao X, et al
   EphA3/EFNA3 Reverse Signalling Promotes Epithelial-to-Mesenchymal Transition via ERK Pathway to Facilitate Colorectal Cancer Metastasis.
   Dig Dis Sci. 2025;70:3356-3368.
   PubMed         Abstract available
   
   
7. HAIMI M, Baker FA, Vinker S, Safadi R, et al
   Association Between High FIB-4 Score and the Risk of Malignancy Development and Mortality: A Retrospective Longitudinal Case-Control Study.
   Dig Dis Sci. 2025;70:3525-3537.
   PubMed         Abstract available
   
   

   
   Eur J Pediatr

8. HUI WF, Deep A
   Interpreting liver function markers in children on continuous renal replacement therapy for acute liver failure.
   Eur J Pediatr. 2025;184:675.
   PubMed         Abstract available
   
   

   
   Gut

9. GAO C, Wang Y, Zhou G, Shi P, et al
   KIF1Bbeta suppresses hepatocellular carcinoma by transporting and secreting FBLN5 to attenuate the integrin pathway.
   Gut. 2025 Oct 13:gutjnl-2025-336230. doi: 10.1136/gutjnl-2025-336230.
   PubMed         Abstract available
   
   

   
   Hepatology

10. SALLMON H, Laufer G, Kurath-Koller S, Kramer P, et al
    Letter to the editor: Esophageal varices in Fontan patients - circulatory or hepatic failure?
    Hepatology. 2025 Oct 13. doi: 10.1097/HEP.0000000000001573.
    PubMed        
    
    
11. ZHANG X, Gong H, Gu K, Chen D, et al
    Letter to the Editor: Re-evaluating the clinical relevance of the RIPPLY1-TBX19 Axis in CTNNB1-Mutant hepatocellular carcinoma.
    Hepatology. 2025 Oct 14. doi: 10.1097/HEP.0000000000001572.
    PubMed        
    
    
12. PATIDAR KR, Sharma P
    Time to focus on POCUS For AKI management in cirrhosis.
    Hepatology. 2025 Oct 16. doi: 10.1097/HEP.0000000000001583.
    PubMed        
    
    
13. KHALID MB, Ilyas SI
    Surgical resection for hepatocellular carcinoma: Leave no TACE?
    Hepatology. 2025;82:1039-1040.
    PubMed        
    
    
14. WANG X, Zhang L, Dong B
    Molecular mechanisms in MASLD/MASH-related HCC.
    Hepatology. 2025;82:1303-1324.
    PubMed         Abstract available
    
    
15. NOUREDDIN M
    MASH clinical trials and drugs pipeline: An impending tsunami.
    Hepatology. 2025;82:1325-1340.
    PubMed         Abstract available
    
    
16. UNALP-ARIDA A, Ruhl CE
    Prevalence of metabolic dysfunction-associated steatotic liver disease and fibrosis defined by liver elastography in the United States using National Health and Nutrition Examination Survey 2017-March 2020 and August 2021-August 2023 data.
    Hepatology. 2025;82:1256-1273.
    PubMed         Abstract available
    
    
17. NEWTON KP, Jayasekera D, Blackford AL, Behling C, et al
    Longitudinal response to standard of care in pediatric metabolic dysfunction-associated steatotic liver disease: Rates of improvement and worsening, and factors associated with outcomes.
    Hepatology. 2025;82:1198-1210.
    PubMed         Abstract available
    
    
18. ROUSSEAU D, Bonnafous S, Soysouvanh F, Sarrail D, et al
    CD44 in myeloid cells is a major driver of liver inflammation and injury in alcohol-associated liver disease.
    Hepatology. 2025;82:1211-1228.
    PubMed         Abstract available
    
    
19. SERPER M, Tang H, Zhang S, McCullough A, et al
    Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.
    Hepatology. 2025;82:1187-1197.
    PubMed         Abstract available
    
    
20. WANG L, Dong W, Fan L, Kong H, et al
    Repression of the ERRgamma-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury.
    Hepatology. 2025;82:1138-1154.
    PubMed         Abstract available
    
    
21. MOECKLI B, Wassmer CH, El Hajji S, Kumar R, et al
    Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study.
    Hepatology. 2025 Mar 5. doi: 10.1097/HEP.0000000000001289.
    PubMed         Abstract available
    
    
22. HARTMANN P, Mouzaki M, Hassan S, Kehar M, et al
    Call to action-Pediatric MASLD requires immediate attention to curb health crisis.
    Hepatology. 2025;82:1341-1351.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

23. FRANSSEN S, Rousian M, Filipe WF, Buisman FE, et al
    Hepatic Arterial Infusion Pump Chemotherapy in Patients With Unresectable Intrahepatic Cholangiocarcinoma-PUMP-2 Trial.
    J Clin Oncol. 2025 Oct 13:JCO2500923. doi: 10.1200/JCO-25-00923.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

24. NAKADAI Y, Ojiro K, Kasuga R, Chu PS, et al
    Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study.
    J Gastroenterol. 2025 Oct 12. doi: 10.1007/s00535-025-02310.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

25. AGARWAL A, Pachisia AV, Agarwal S, Mehta S, et al
    Celiac Disease and Its Impact on Liver-Related Outcomes in Patients With All-Cause Cirrhosis: The CELIHEP Study.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70082.
    PubMed         Abstract available
    
    
26. XU L, Liu J
    Comment on Impact of Renin-Angiotensin-Aldosterone System Inhibitors on Liver-Related Events and Mortality in Patients With Cirrhosis: A Meta-Analysis of Real-World Evidence.
    J Gastroenterol Hepatol. 2025 Oct 16. doi: 10.1111/jgh.70114.
    PubMed        
    
    

    
    J Hepatol

27. GARG P, Verma N, Jalan R
    Reply to: RIPK3 in acutely decompensated cirrhosis: prognostic promise and analytic pitfalls.
    J Hepatol. 2025 Oct 9:S0168-8278(25)02549-8. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
28. THEVENOT T, Desmarets M, Tio G
    Primary prophylaxis of spontaneous bacterial peritonitis using rifaximin in patients with severe cirrhosis and ascites, not the end of the story?
    J Hepatol. 2025 Oct 9:S0168-8278(25)02551-6. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
29. WEDEMEYER H, Tacke F, Newsome P, Ratziu V, et al
    The first human xenogeneic liver transplantation - A landmark event, but what does it mean for hepatology?
    J Hepatol. 2025 Oct 9:S0168-8278(25)02496-1. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    
30. TELLEZ L, Donate J, Guerrero A, Beraza IA, et al
    Early portopulmonary hypertension predicts mortality in patients with cirrhosis: insights from the PORTO-DETECT cohort.
    J Hepatol. 2025 Oct 9:S0168-8278(25)02490-0. doi: 10.1016/j.jhep.2025.
    PubMed         Abstract available
    
    
31. QIAN S, He Y
    Alcohol consumption potentiates second-hit events in HBV-induced hepatocellular carcinoma.
    J Hepatol. 2025 Oct 10:S0168-8278(25)02548-6. doi: 10.1016/j.jhep.2025.
    PubMed        
    
    

    
    Oncogene

32. CHEN Q, Liang Y, Li Y, Li X, et al
    PSME3 drives Tregs infiltration and anti-PD1 resistance in hepatocellular carcinoma by regulating FBXL7/PTEN-mediated metabolic reprogramming.
    Oncogene. 2025 Oct 15. doi: 10.1038/s41388-025-03593.
    PubMed         Abstract available
    
    

    
    PLoS One

33. SHEN P, Xiong H, Luo QH, Ding YF, et al
    Investigating the common genetic basis between inflammatory bowel disease and metabolic syndrome through genomic structural equation modeling.
    PLoS One. 2025;20:e0334456.
    PubMed         Abstract available
    
    
34. WANG Q, Su Y, Niu J, Wang Y, et al
    Nonlinear association between TyG-BMI and MAFLD: A cross-sectional study.
    PLoS One. 2025;20:e0331140.
    PubMed         Abstract available
    
    
35. CORBALAN JJ, Jagadeesan P, Nickels JT Jr
    Humanized monoacylglycerol acyltransferase 2 mice on a high-fat diet exhibit impaired liver detoxification during metabolic dysfunction-associated steatotic liver disease.
    PLoS One. 2025;20:e0334213.
    PubMed         Abstract available
    
    
36. TAKAURA K, Tsuchiya K, Taguchi M, Tokunaga Y, et al
    Clinical outcome of radiofrequency ablation in patients with hepatocellular carcinoma aged 80 years and older.
    PLoS One. 2025;20:e0334712.
    PubMed         Abstract available
    
    
37. SCHREINER AD, Zhang J, Gebregziabher M, Marsden J, et al
    The association of race with time to severe liver disease diagnoses.
    PLoS One. 2025;20:e0334016.
    PubMed         Abstract available
    
    
38. WANG Y, Cai T, Chen Y, Liu W, et al
    KIF18A induces the EMT process of hepatoma cells through the 5-LOX-dependent arachidonic acid pathway.
    PLoS One. 2025;20:e0333385.
    PubMed         Abstract available
    
    
39. YANG X, Wang G, Min Z, Lv L, et al
    The prognostic value of the direct bilirubin to albumin ratio in critically ill patients with cirrhosis: Insights from MIMIC-IV database.
    PLoS One. 2025;20:e0334591.
    PubMed         Abstract available
    
    

    
    Transplant Proc

40. ZUBKOV MR, Moore HB, Baimas-George M, Arrigain S, et al
    Is Model for End-stage Liver Disease 3.0 Better Than Model for End-stage Liver Disease? Evaluating the Association of Liver Disease Severity Scores With Perioperative Complications in Liver Transplant Recipients.
    Transplant Proc. 2025 Sep 23:S0041-1345(25)00442.
    PubMed         Abstract available
    
    
41. GUO WB, Guo XJ, Zheng MY, Xie XC, et al
    Analysis of the Cost-Effectiveness of Treatment Strategies for Acute-on-Chronic Liver Failure.
    Transplant Proc. 2025;57:1554-1559.
    PubMed         Abstract available
    
    
42. SAEGUSA Y, Ohira M, Honmyo N, Nakano R, et al
    Outcomes of Liver Transplantation Among Patients Diagnosed With Acute-on-Chronic Liver Failure: A Single-Center Experience.
    Transplant Proc. 2025 Jul 17:S0041-1345(25)00321.
    PubMed         Abstract available
    
    

    
    Transplantation

43. HASJIM BJ, Paukner M, Kwong AJ, Bhat M, et al
    Impact of the 6-mo Wait Policy on Transplantation, Resection, and Ablation Outcomes for Patients With Hepatocellular Carcinoma: A National Cancer Database Analysis.
    Transplantation. 2025 Oct 13. doi: 10.1097/TP.0000000000005536.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.